ArticlePharmaceutical research2025
Developing Subcutaneous Formulations for Irisin as a Potential Therapeutic.
Article in Pharmaceutical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeIrisin, a hormone secreted by skeletal muscle during physical exercise, shows promise for health benefits. However, limited research on its characterization and formulation development has impeded its pharmaceutical development. This study aimed to develop fit-for-purpose subcutaneous formulations for irisin.
methodsIrisin was expressed in E.coli and purified. The prepared irisin was characterized using orthogonal biophysical techniques, and its biological activity was assessed. Subcutaneous formulations were then developed by screening pH, excipients, and formats (lyophilized vs. aqueous), and the product stability profiles were investigated under various conditions.
resultsIrisin was successfully expressed in both soluble and refolded forms, and after purification, both forms displayed similar biophysical properties and induced adipocyte browning. Lyophilized formulations, incorporating phosphate buffer (pH 7), sucrose or trehalose, and polysorbate 80, preserved irisin's properties and bioactivity after lyophilization and could be rapidly reconstituted for subcutaneous administration. The formulations also remained stable at 40°C/75% RH for at least one month.
conclusionsThese findings lay a foundation for advancing irisin-based therapies for obesity and related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.